KIT and breast carcinoma: Henceforth, the KIT protein was determined to be an “RRbc target” based on four significant properties: Firstly, the KIT protein was influenced in primary breast tumors, identified through cluster analysis; secondly, the KIT protein has radioresistant behavior, demonstrated through DEG analysis of GSE210306; thirdly, the KIT protein is observed as a cancer drug target as assessed through database screening; and finally, KIT expression influences the survival rate of patients with breast cancer.